{"disease":{"id":"pathway-mutant-myelodysplastic-syndromes","name":"pathway mutant myelodysplastic syndromes"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06284460","title":"Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}